Skip to main content
. 2016 Nov 25;35:97. doi: 10.1186/s40880-016-0162-7

Fig. 1.

Fig. 1

Proposed mechanism of acquired resistance to the multikinase inhibitor sorafenib in hepatocellular carcinoma (HCC). Highly angiogenic HCCs are initially responsive to sorafenib treatment. Over time, tumor cells become more invasive which promotes co-option of liver vessels in the face of angiogenesis blockade. EMT epithelial-to-mesenchymal transition